Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 7, 2024

OverT Bio secures $16m in seed funding for cell therapy development

Data-driven biotechnology company OverT Bio has secured $16m in a seed funding round to expand its discovery platforms aimed at developing cellular therapies for solid tumours.

Continue
The investment will support OverT Bio's efforts to develop potentially curative treatments for advanced solid tumours. Credit: Colin Behrens from Pixabay.
May 6, 2024

FDA accepts BLA for BMS’ subcutaneous nivolumab to treat solid tumours

A regulatory decision on the approval for BMS’ subcutaneous nivolumab under the Prescription Drug User Fee Act (PDUFA) is expected on 28 February next year. Credit: Bristol-Myers Squibb Company.
May 3, 2024

Latus Bio secures $54m for CNS gene therapy development

Latus's capsid variants have shown high gene expression in targeted CNS locations. Credit: Arek Socha from Pixabay.

Contracts

December 14, 2022

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Micrograph of psoriasis vulgaris. Credit: Jenny Giang, Marc A. J. Seelen, Martijn B. A. van Doorn, Robert Rissmann,Errol P. Prens and Jeffrey Damman/ commons.wikimedia.org.

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Kite, Refuge sign license deal for gene expression platform for blood cancers

Deals

Deals April 18, 2024

Biocon signs licensing and supply deal for diabetes drug in Brazil

Pharmaceutical Business Review

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Kindeva Drug Delivery acquires Summit Biosciences

Popular

  1. Celltrion secures new public tenders for two biosimilars in Peru
  2. Scenic Biotech, Bristol Myers Squibb to develop new drug targets
  3. Genmab and Pfizer’s TIVDAK sBLA secures full FDA approval
  4. FDA approves Ractigen Therapeutics’ RAG-01 IND for bladder cancer
  5. PRISM, ONO to co-create development candidate for oncology target

PRESS RELEASES

Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK

Suppliers

Whitepapers

Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation